About Diadexus
Diadexus is a company based in San Francisco (United States) founded in 1997 was acquired by Diazyme Laboratories in April 2016. Diadexus has raised $49.2 million across 3 funding rounds from investors including Burrill and Company, Diazyme Laboratories and Scale Venture Partners. Diadexus offers products and services including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay. Diadexus operates in a competitive market with competitors including SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others.
- Headquarter San Francisco, United States
- SectorsHealthcare
- Website diadexus.com
- Social LinkedIn X Facebook
- Acquired by Diazyme Laboratories (Apr 2016)
- Legal Name Diazyme Laboratories Inc.
- Total Equity Funding$49.2M (USD)
in 3 rounds
- Latest Funding Round$4.5M (USD), Debt – Conventional
Jun 2010
- InvestorsBurrill and Company
& 5 more
- Acquired byDiazyme Laboratories
(Apr 2016)
Products & Services of Diadexus
Diadexus offers a comprehensive portfolio of products and services, including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay.
Immunoturbidimetric assay for detecting inflammatory markers
Test for pancreatic function in clinical samples
Fully-automated chemistry analyzer for lab testing
Chemiluminescent assay for cardiovascular markers
Quantitative test for sepsis and infection indicators
Funding Insights of Diadexus
Diadexus has successfully raised a total of $49.2M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.5 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.2M
- Total Rounds 3
- Last Round Debt – Conventional — $4.5M
- First Round $40M
(Jan 2007)
- Investors Count 5
All 3 funding rounds of Diadexus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2010 | $4.5M | Debt – Conventional | – | – | – |
| Feb 2009 | $9.2M | Series F | – | – | |
| Jan 2007 | $40M | Series E | – | – |
6 investors in total: 6 institutional.
Investors in Diadexus
Diadexus has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Burrill and Company, Diazyme Laboratories and Scale Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital investments are focused on US companies. | – | scalevp.com | Foster City, United States | |
Venture capital firm focused on multiple sectors | – | brooksidecapital.com | San Francisco, United States | |
Growth & late stage life sciences and tech focused venture capital firm funding companies in the US | – | mosaixventures.com | Chicago, United States | |
Early-stage tech startups are invested in by Rho Capital Partners. | – | rho.com | New York, United States | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Clinical diagnostic reagents and enzyme-based test kits are developed. | 2000 | diazyme.com | Poway, United States |
Investor details for Diadexus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Diadexus
4 dated milestones of Diadexus across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Diadexus is founded.
- Funding First funding round of $40.0M.
- Funding Latest funding round, Debt – Conventional, of $4.5M.
- Exit Acquired by Diazyme Laboratories.
Competitors of Diadexus
Diadexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sdbiosensor.com | 2001 | Suwon-si, South Korea | – | – | Biosensors for point-of-care diagnostics are developed by SD Biosensor. | |
| genincode.com | 2018 | Manchester, United Kingdom | $4.48M | 26 | Genetic and clinical data are integrated for precision cardiac medicines. | |
| spectrawave.com | 2012 | Waltham, United States | $79.88M | 36 | Photonic imaging diagnostics for cardiovascular disease treatment are provided. | |
| realviewimaging.com | 2008 | Yokneam Illit, Israel | $25M | – | 3D holographic display solutions for medical imaging are provided. | |
| lepumedical.com | 1999 | Beijing, China | – | – | Interventional cardiology devices are developed and marketed globally. | |
| bostonheartdiagnostics.com | 2007 | Framingham, United States | $10.34M | – | Diagnostics for personalized cardiovascular disease management are developed. | |
| prevenciomed.com | 2006 | Kirkland, United States | $5.68M | – | Protein-based diagnostics and prognostics for cardiovascular diseases are developed. | |
| spectrum-dynamics.com | 2000 | Morges, Switzerland | – | – | Cardiac imaging systems are manufactured using advanced molecular technologies. | |
| proximdx.com | 2010 | Sunnyvale, United States | $22.9M | – | Handheld immunodiagnostic devices for cardiac vascular diseases are developed. |
Detailed competitors of Diadexus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diadexus
Websites that share an audience with Diadexus (diadexus.com).
Websites whose visitors overlap most with Diadexus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mattek.com | 100% | 17.4K | #1,441,008 | View details |
Latest news on Diadexus
Complete news archive for Diadexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Diadexus
10 companies that operate in the same segment as Diadexus (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diadexus
Diadexus was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Diadexus is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Diadexus is a funded company, having raised a total of $49.2M across 3 funding rounds to date. The company's 1st funding round was a Series E of $40M, raised on Jan 2007.
Diadexus develops molecular diagnostic tests for cardiovascular disorders. It currently has two products on the market (under the PLAC trademark) that test Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. the PLAC Test ELISA kit that assesses the risk of coronary heart disease and ischemic stroke associated with atherosclerosis, while the PLAC Test for Lp-PLA2 Activity that evaluates the risk of coronary heart disease in patients with no prior history of cardiovascular disease. In addition, the company has other biomarker-based tests for heart failure in the pipeline. The lead heart failure biomarker proADM (mid-regional pro-adrenomedullin) has entered formal development on the ELISA platform for a planned 510(k) regulatory submission to the FDA in early 2016. In 2014, Diadexus and Vaxgen entered into a reverse merger agreement, and the combined company was renamed Diadexus.
Diadexus's top competitors include GEN inCode, SD Biosensor and SpectraWAVE.
Diadexus offers Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay.
Diadexus has 6 investors. Key investors include Burrill and Company, Diazyme Laboratories, Scale Venture Partners, Brookside Capital, and Mosaix Ventures.
Diadexus operates through Diazyme Laboratories Inc..
Yes. Diadexus was acquired by Diazyme Laboratories in April 2016.